Clinical remission · Induction of Remission in Medically Refractory Crohn's Disease
Summary of findings table ‐ Stem Cell showed no clear difference in clinical remission compared with placebo or Control (low certainty).
1 finding from 1 review
CDAI <150 at 24 weeks · Induction of Remission in Medically Refractory Crohn's Disease
It is very uncertain whether summary of findings table ‐ Stem Cell changes CDAI <150 at 24 weeks compared with placebo or Control (very low certainty).
1 finding from 1 review
Fistula Closure short‐term · Induction of Remission in Medically Refractory Crohn's Disease
Summary of findings table ‐ Stem Cell may leads to higher fistula Closure short‐term compared with placebo or Control (low certainty).
1 finding from 1 review
Fistula closure in long‐term · Induction of Remission in Medically Refractory Crohn's Disease
Summary of findings table ‐ Stem Cell may leads to higher fistula closure in long‐term compared with placebo or Control (low certainty).
1 finding from 1 review
Total adverse events · Induction of Remission in Medically Refractory Crohn's Disease
It is very uncertain whether summary of findings table ‐ Stem Cell changes total Adverse Events compared with placebo or Control (very low certainty).
1 finding from 1 review
Serious adverse events · Induction of Remission in Medically Refractory Crohn's Disease
Summary of findings table ‐ Stem Cell showed no clear difference in serious Adverse Events compared with placebo or Control (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Induction of Remission in Medically Refractory Crohn's Disease
It is very uncertain whether summary of findings table ‐ Stem Cell changes withdrawal due to adverse events compared with placebo or Control (very low certainty).
1 finding from 1 review
Mortality attributable to hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
It is very uncertain whether summary of findings: Heparin changes mortality attributable to hepatic veno‐occlusive disease ( compared with low molecular weight heparin (very low certainty).
1 finding from 1 review
Mortality attributable to hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
It is very uncertain whether summary of findings: Heparin changes mortality attributable to hepatic veno‐occlusive disease ( compared with prostaglandin E1 (very low certainty).
1 finding from 1 review
Mortality attributable to hepatic veno‐occlusive disease ( · People undergoing stem cell transplant with haematological malignancies
It is very uncertain whether summary of findings: Glutamine changes mortality attributable to hepatic veno‐occlusive disease ( compared with placebo (very low certainty).
1 finding from 1 review
Mortality attributable to hepatic veno‐occlusive disease ( · Children undergoing stem cell transplant with malignant and non‐malignant diseases and risk factors for hepatic veno‐occlusive disease
Summary of findings: Defibrotide showed no clear difference in mortality attributable to hepatic veno‐occlusive disease ( compared with no treatment (low certainty).
1 finding from 1 review
Mortality attributable to hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality attributable to hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
It is very uncertain whether summary of findings: Ursodeoxycholic acid changes mortality attributable to hepatic veno‐occlusive disease ( compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Mortality attributable to hepatic veno‐occlusive disease ( · People undergoing stem cell transplant with malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality attributable to hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
It is very uncertain whether summary of findings: Low molecular weight heparin changes mortality attributable to hepatic veno‐occlusive disease ( compared with prostaglandin E1 (very low certainty).
1 finding from 1 review
Mortality attributable to hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
It is very uncertain whether summary of findings: Antithrombin III plus heparin changes mortality attributable to hepatic veno‐occlusive disease ( compared with heparin alone (very low certainty).
1 finding from 1 review
Mortality attributable to hepatic veno‐occlusive disease ( · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases or aplastic anaemia
Summary of findings: Heparin showed no clear difference in mortality attributable to hepatic veno‐occlusive disease ( compared with no treatment (low certainty).
1 finding from 1 review